Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

NCT01327612 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Carcinoid
Colorectal Cancer
Locally Advanced
Lymphoma
Metastatic Cancer
Non-Small Cell Lung Cancer
Sarcoma
Solid Tumors

Interventions

DRUG: Modified FOLFOX6
BIOLOGICAL: Conatumumab
BIOLOGICAL: Ganitumab
BIOLOGICAL: Bevacizumab

Sponsor

Amgen